Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: A phase II study

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  Rosati, G ^a   Bilancia, D ^a   Germano, D ^a   Dinota, A ^a   Romano, R ^a   Reggiardo, G ^b   Manzione, L ^a  

^a SAN CARLO HOSPITAL   (Italy)

^b Medi Service   (Italy)

Author keywords

Capecitabine; Docetaxel; Gastric cancer; Second line chemotherapy

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; TAXOID;

ADULT; AGED; ALOPECIA; ANEMIA; ASTHENIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; ONYCHOLYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; ARTICLE; DOSE RESPONSE; DRUG ADMINISTRATION; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; PERITONEUM TUMOR; STOMACH TUMOR; TUMOR RECURRENCE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; TAXOIDS;

EID: 35748940992     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm241     Document Type: Conference Paper

References (19)

1. National Comprehensive Cancer Network Proceedings. NCCN practice guidelines for upper gastrointestinal carcinomas. Oncology 1998; 12: 179-223.
2. Assersohn L, Brown G, Cunningham D et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004; 15: 64-69.
3. Wang LG, Liu XM, Kreis W et al. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother Pharmacol 1999; 44: 355-361.
4. Einzig AI, Neuberg D, Remick SC et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13: 87-93.
5. Sulkes A, Smyth J, Sessa C et al. Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994; 70: 380-383.
6. Giuliani F, Gebbia V, De Vita F et al. Docetaxel as salvage therapy in advanced gastric cancer: A phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res 2003; 23: 4219-4222.
7. Koizumi W, Saigenji K, Ujiie S et al. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Clinical Study Group of Capecitabine. Oncology 2003; 64: 232-236.
8. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/ Taxotere in human xenografts. Clin Cancer Res 1998; 4: 1013-1019.
9. Pronk LC, Vasey P, Sparreboom A et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer 2000; 83: 22-29.
10. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
11. Chun JH, Kim HK, Lee JS et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005; 28: 188-194.
12. Park YH, Ryoo B-Y, Choi S-J, Kim H-T. A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2004; 90: 1329-1333.
13. Giordano KF, Jatoi A, Stella PJ et al. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: A phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006; 17: 652-656.
14. Kim JG, Sohn SK, Kim DH et al. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 2005; 68: 190-195.
15. Orditura M, Martinelli E, Galizia G et al. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: A phase II study. Ann Oncol 2006; 17: 1529-1532.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
17. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trials of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346-353.
18. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-458.
19. Leonard R, O'Shaughnessy J, Vukelja S et al. Detailed analysis of a randomised phase III trial: Can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006; 17: 1379-1385.